Getting Non-Directional with Sarepta
Research - If you took our Sarepta Therapeutics (SRPT) trade from February, the diagonal has more than doubled in value. This is a great spot to cut … Continue Reading
Read NowResearch
GW Pharma Spotlights Epilepsy; Other Opportunities Abound
Research - The 100% move from GW Pharmaceuticals (GWPH) on Monday is a good opportunity to circle back on another mid-cap epilepsy player that’s down 40% year-to-date and 60% from its highs last year.
Premium: Read Now
Quietly Plugging Away, Synergy in 2016
Research - It’s been some time since we’ve revisited Synergy Pharmaceuticals (SGYP). The company continues to guide for phase 3 plecanatide IBS-C data in the first half … Continue Reading
Premium: Read Now
UniQure’s Finally a Sleeper: Timelines in Hemophilia
Research - UniQure (QURE) has essentially traded sideways since the company presented the first results from their ongoing open-label study of hemophilia gene therapy AMT-060 in January.
Read Now
That Rally! For Now, Optimism is Back
Insights - Biotech had a Super Wednesday after Bernie Sanders’ not-so-super Tuesday.
Premium: Read Now
A Quick Note on a Bizarre Conference Call
Research - Rockwell Medical (RMTI) reported fourth quarter and full-year 2015 results after the bell this evening. The accompanying conference call was bizarre, and the stock is … Continue Reading
Read Now
Nothing New From This Earnings Update
Research - Chimerix (CMRX) said in a conference call this morning that they now expect results from AdVise, which we wrote about last week, this spring.
Premium: Read Now